The high court in North Dakota voted to protect abortion in that state; an outside panel of FDA expert advisors voted to support a full approval for Paxlovid; Sanofi follows competitors' price caps for insulin.
North Dakota Supreme Court Blocks State’s Abortion Ban
In a majority ruling, North Dakota’s Supreme Court backed a lower court’s decision to block a state-wide abortion ban, according to The New York Times.Although the ruling does not determine the final outcome of abortion rights, for now, it allows abortion to remain legal in North Dakota until nearly 22 weeks after a woman’s last period. Currently, 2 state Supreme Courts have made final decisions, with South Carolina ruling abortion was protected under constitutional law, while Idaho ruled that abortion was not protected under its Constitution.
FDA Advisors Approve Paxlovid for Treating COVID-19 in High-Risk Adults
The US Food and Drug Administration (FDA) voted 16-1 supporting the full approval of Paxlovid as a treatment of mild and moderate COVID-19 in high-risk adults, according to CNN. In this decision, the FDA concluded that Paxlovid was not associated with COVID-19 rebounds, with findings suggesting that rebound may occur in a subset of infections due to natural progression of the disease. Furthermore, the FDA found no major safety concerns, but has identified 137 medications with Paxlovid drug-drug interactions (DDIs) that may have adverse outcomes.
Sanofi Follows After Eli Lilly and Novo Nordisk with Insulin Price Cap
Sanofi announced that it will cap out-of-pocket costs at $35 for its most popular insulin drug, Lantus [insulin glargine (rDNA origin) injection], according to NBC News. Sanofi, Eli Lilly, and Novo Nordisk make up about 90% of the US insulin market, and have been feeling pressure from lawmakers and advocacy groups to lower the cost of insulin drugs following the Inflation Reduction Act. Under this act, starting in 2024, drugmakers will be penalized for raising drug prices faster than the rate of inflation.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More